Company intelligence / Profile preview

PKvitality

Paris, Île-de-France, Francepkvitality.com ↗

Ownership: Private
Employees: ~34
Development stage: Phase 1

Overview

The K’Watch Glucose device has shown excellent pre-clinical results and entered First-In-Human studies at the end of 2021 to demonstrate precision and accuracy. Clinical validation and regulatory clearance are pending; no commercial launch yet.

Therapeutic areas: OtherEndocrinology
Modalities: Device (wearable)Microneedle patch (for analyte detection)Non-pharmacological therapy (monitoring only)
Industry: Metabolite Diagnostics

Partnerships

AMCR Institute Inc. – clinical research partner for diabetes/metabolic trialsEIC Fund/EIT Health – funding partnersBeurer GmbH – investor/partner in Series A round

Beyond the preview

Go deeper on PKvitality.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PKvitality.

Explore the full profile